ESPEYB15 9 Oncology and chronic disease Late consequences of tumour therapy: prevention and monitoring (3 abstracts)
The Jesse Z. and Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel
To read the full abstract: J Pediatr Endocrinol Metab. 2017;30:869-877
Several previous studies had focused on the early risk of metabolic syndrome or its components in survivors of childhood acute lymphoblastic leukaemia (ALL), while fewer data are available on pubertal development in these subjects. The merit of this study was to carefully investigate growth and pubertal development in a large cohort of childhood ALL survivors, who were treated and followed at a single institution. The cohort included a relatively high proportion of patients who reached final adult height and completed pubertal development (63%); furthermore, relevant parameters such as target height were considered. Although the cohort is heterogeneous regarding to treatments (five successive protocols used between 1985 and 2011), the study group is adequately homogeneous regarding to the primary disease and not having undergone bone marrow transplantation. The results show that growth pattern and pubertal development are normal in most survivors of childhood ALL treated with chemotherapy alone. Increased risk of endocrine disturbances, particularly early puberty and reduced final height, was observed in patients exposed to CRT.